Track Catalyst Biosciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Catalyst Biosciences, Inc. CBIO · Stock Open Catalyst Biosciences, Inc. in new tab

14.15 USD
EPS
-7.63
P/B
3.10
Target Price
31.50 USD
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
EPS-7.63
Book Value4.77
Price to Book3.10
Debt/Equity0.88
% Insiders0.268%
Estimates
Forward P/E-5.61
Forward EPS-2.63
Target Mean Price31.50

DCF valuation

Model fair value for Catalyst Biosciences, Inc. (CBIO)
Result
Sign in to run the valuation for CBIO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
6 analysts · consensus None · mean target 31.50 USD (low 27.00, high 36.00) · as of 12 Nov 2026
Low 27.00
Mean 31.50
High 36.00
Price 14.15
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Catalyst Biosciences, Inc. Logo Catalyst Biosciences, Inc. Analysis (CBIO)

United States Health Care Official Website Stock

Is Catalyst Biosciences, Inc. a good investment? Catalyst Biosciences, Inc. (CBIO) is currently trading at 14.15 USD. Market analysts have a consensus price target of 31.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Catalyst Biosciences, Inc. is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is -2.63.

Investor FAQ

Does Catalyst Biosciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Catalyst Biosciences, Inc.?

Catalyst Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -7.63.

Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
NMS (United States) CBIO
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2023
24.24 USD
Jan. 13, 2023 0.2400
Jan. 13, 2023 24.0000
▸2022
144.43 USD
Sept. 21, 2022 1.4300
Sept. 21, 2022 143.0000
Stock Splits
Split Date Split Ratio to 1
June 16, 2025 1:100
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion